Information de reference pour ce titreAccession Number: | 00009602-201601300-00032.
|
Author: | Jankovic, Jovana a; Djekic, Ljiljana b,*; Dobricic, Vladimir c; Primorac, Marija b
|
Institution: | (a)Apoteka Jankovic, Milosa Bajica 13, 21000 Novi Sad, Serbia (b)University of Belgrade, Faculty of Pharmacy, Department of Pharmaceutical Technology and Cosmetology, Vojvode Stepe 450, 11221 Belgrade, Serbia (c)University of Belgrade, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Vojvode Stepe 450, 11221 Belgrade, Serbia
|
Title: | Evaluation of critical formulation parameters in design and differentiation of self-microemulsifying drug delivery systems (SMEDDSs) for oral delivery of aciclovir.[Article]
|
Source: | International Journal of Pharmaceutics. 497(1-2):301-311, January 2016.
|
Abstract: | : The study investigated the influence of formulation parameters for design of self-microemulsifying drug delivery systems (SMEDDSs) comprising oil (medium chain triglycerides) (10%), surfactant (Labrasol(R), polysorbate 20, or Kolliphor(R) RH40), cosurfactant (Plurol(R) Oleique CC 497) (q.s. ad 100%), and cosolvent (glycerol or macrogol 400) (20% or 30%), and evaluate their potential as carriers for oral delivery of a poorly permeable antivirotic aciclovir (acyclovir). The drug loading capacity of the prepared formulations ranged from 0.18-31.66 mg/ml. Among a total of 60 formulations, three formulations meet the limits for average droplet size (Z-ave) and polydispersity index (PdI) that have been set for SMEDDSs (Z-ave <= 100 nm, PdI < 0.250) upon spontaneous dispersion in 0.1 M HCl and phosphate buffer pH 7.2. SMEDDSs with the highest aciclovir loading capacity (24.06 mg/ml and 21.12 mg/ml) provided the in vitro drug release rates of 0.325 mg cm-2 min-1 and 0.323 mg cm-2 min-1, respectively, and significantly enhanced drug permeability in the parallel artificial membrane permeability assay (PAMPA), in comparison with the pure drug substance. The results revealed that development of SMEDDSs with enhanced drug loading capacity and oral delivery potential, required optimization of hydrophilic ingredients, in terms of size of hydrophilic moiety of the surfactant, surfactant-to-cosurfactant mass ratio (Km), and log P of the cosolvent.
(C) 2016Elsevier, Inc.
|
Author Keywords: | Self-dispersing drug delivery systems; Self-microemulsifying drug delivery systems (SMEDDS); Aciclovir; Acyclovir; In vitro drug release; Parallel artificial membrane permeability assay (PAMPA).
|
References: | Amidon, G.L., Lennernas, H., Shah, V.P., Crison, J.R., 1995. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12(3), 413-420.
Arnal, J., Gonzalez-Alvarez, I., Bermejo, M., Amidon, G.L., Junginger, H.E., Kopp, S., Midha, K.K., Shah, V.P., Stavchansky, S., Dressman, J.B., Barends, D.M., 2008. Biowaiver monographs for immediate release solid oral dosage forms: aciclovir. J. Pharm. Sci. 97(12), 5061-5073.
Bergstrom, C.A., Strafford, M., Lazorova, L., Avdeef, A., Luthman, K., 2003. Absorption classification of oral drugs based on molecular surface properties. J. Med. Chem, 46, 558-570.
Chen, M.L., 2008. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective. Adv. Drug Deliv. Rev, 60, 768-777.
Bermejo, M., Avdeef, A., Ruiz, A., Nalda, R., Ruell, J.A., Tsinman, O., Gonzalez, I., Fernandez, C., Sanchez, G., Garrigues, T.M., Merino, V., 2004. PAMPA-a drug absorption in vitro model [7] comparing rat in situ Caco-2, and PAMPA permeability of fluoroquinolones. Eur. J. Pharm. Sci, 21, 429-441.
Charman, W.N., 2000. Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J. Pharm. Sci, 89, 967-978.
De Clercq, E., 2013. Selective anti-herpesvirus agents. Antivir. Chem. Chemother. 23(3), 93-101.
Dedakia, J., Majumdar, S.H., 2012. Formulation and evaluation of microemulsion based tablets of acyclovir for better patient compliance. Int. J. Pharm. Technol. Res. 4(4), 1730-1734.
Djekic, L., Ibric, S., Primorac, M., 2011. Application of artificial neural networks (ANNS) in development of pharmaceutical microemulsions. In: Kwon, S.J. (Ed.), Focus on Artificial Neural Networks. Nova Science Publishers Inc., New York, pp. 1-28.
Djekic, L., Cirkovic, V., Heleta, M., Krajisnik, D., Primorac, M., 2013. Water-dilutable biocompatible microemulsion systems: design and characterisation. Tenside Surfactants Deterg. 50(6), 409-413.
Djekic, L., Primorac, M., 2008. The influence of cosurfactants and oils on the formation of pharmaceutical microemulsions based on PEG-8 caprylic/capric glycerides. Int. J. Pharm. 352(1-2), 231-239.
Elion, G.B., 1982. Mechanism of action and selectivity of acyclovir. Am. J. Med. 73(1A), 7-13.
Fatouros, D.G., Karpf, D.M., Nielsen, F.S., Mullertz, A., 2007. Clinical studies with oral lipid based formulations of poorly soluble compounds. Ther. Clin. Risk Manag. 3(4), 591-604.
Ghosh, P.K., Majithiya, R.J., Umrethia, M.L., Murthy, R.S.R., 2006. Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability. AAPS Pharm.Sci.Technol. 7(3), 172-177.
Goddeeris, C., Cuppo, F., Reynaers, H., Bouwman, W.G., Van den Mooter, G., 2006. Light scattering measurements on microemulsions: estimation of droplet sizes. Int. J. Pharm, 312, 187-195.
Hansch, C., Leo, A., Hoekman, D.Exploring QSAR-Hydrophobic, Electronic, and Steric Constants. 1995. American Chemical Society. Washington, DC. 7.
Hauss, D.J., 2007. Oral lipid-based formulations. Adv. Drug Deliv. Rev. 59(7), 667-676.
Hou, T.J., Zhang, W., Xia, K., Qiao, X.B., Xu, X.J., 2004. ADME evaluation in drug discovery. 5. Correlation of Caco-2 permeation with simple molecular properties. J. Chem. Inf. Comput. Sci, 44, 1585-1600.
Huiling, M., Rene, H., Mullertza, A.B., 2013. Lipid-based formulations for oral administration of poorly water-soluble drugs. Int. J. Pharm, 453, 215-224.
Kansy, M., Senner, F., Gubernator, K., 1998. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J. Med. Chem. 41(7), 1007-1010.
Kohli, K., Chopra, S., Dhar, D., Arora, S., Khar, R.K., 2010. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability. Drug Discov. Today. 15(21-22), 958-965.
Kristl, A., Srcic, S., Vrecer, F., sustar, B., Vojnovic, D., 1996. Polymorphism and pseudopolymorphism: influencing the dissolution properties of the guanine derivative acyclovir. Int. J. Pharm. 139(1-2), 231-235.
Kristl, A., Pecar, S., Kmetec, V., 1999. Are calculated log P values for some guanine derivatives by different computer programs reliable? Int. J. Pharm. 181(2), 219-226.
Krstic, M.Z., Razic, S.S., Djekic, L.M., Dobricic, V.D., Momcilovic, M.A., Vasiljevic, D.D., Ibric, S.R., 2015. Application of a mixture experimental design in the optimization of the formulation of solid self-emulsifying drug delivery systems containing carbamazepine. Lat. Am. J. Pharm. 34(5), 885-894.
Kuentz, M., 2012. Lipid-based formulations for oral delivery of lipophilic drugs. Drug Discov. Today: Technol. 9(2), 97-104.
Kumar, B., Jain, S.K., Prajapati, S.K., 2011. Effect of penetration enhancer DMSO on in-vitro skin permeation of acyclovir transdermal microemulsion formulation. Int. J. Drug Deliv. 3(1), 83-94.
Lein, A., Ng, S.W., 2015. Oral liquids. In: Bouwman, Y., Fenton-May, V., Le Brun, P. (Eds.), Practical Pharmaceutics. An International Guideline for the Preparation, Care and Use of Medicinal Products. KNMP and Springer International Publishing, Switzerland, pp. 77-98.
Lutker, K.M., Quinones, R., Xu, J., Ramamoorthy, A., Matzger, A.J., 2011. Polymorphs and hydrates of acyclovir. J. Pharm. Sci. 100(3), 949-963.
Ma, T.Y., Hollander, D., Krugliak, P., Katz, K., 1990. PEG 400: a hydrophilic molecular probe for measuring intestinal permeability. Gastroenterology, 98, 39-46.
Mehta, P., 2013. Acyclovir: pediatric infectious disease. Antimicro. Clin. Pract. 5(4), 178-180.
Moore, J.W., Flanner, H.H., 1996. Mathematical comparison of dissolution profiles. Pharm. Technol, 20, 64-74.
Mrsny, R.J., 2012. Oral drug delivery research in Europe. J. Controlled Release, 161, 247-253.
Mu, H., Holm, R., Mullertz, A., 2013. Lipid-based formulations for oral administration of poorly water-soluble drugs. Int. J. Pharm, 453, 215-224.
O'Brien, J.J., Campoli-Richards, D.M., 1989. Acyclovir an updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 37(3), 233-309.
Patel, D., Sawant, K.K., 2007. Oral bioavailability enhancement of acyclovir by self-microemulsifying drug delivery systems (SMEDDS). Drug Dev. Ind. Pharm. 33(12), 1318-1326.
Physicians Desk ReferencePDR Network. 67th ed. 2013. LLC. Montvale, NJ. 1203.
Porter, C.J.H., Pouton, C.W., Cuine, J.F., Charman, W.N., 2008. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv. Drug Deliv. Rev. 60(6), 673-691.
Pouton, C.W., 2000. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying, and self-microemulsifying drug delivery systems. Eur. J. Pharm Sci. 11(2), 93-98.
Pouton, C.W., 2006. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur. J. Pharm. Sci, 29, 278-287.
Pouton, C.W., Porter, C.J.H., 2008. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv. Drug Deliv. Rev, 60, 625-637.
Ramadan, E., Borg Th Abdelghani, G.M., Saleh, N.M., 2013. Formulation and evaluation of acyclovir microemulsions. Bull. Pharm Sci., Assiut University. 36(1), 31-47.
Rane, S.S., Anderson, B.D., 2008. What determines drug solubility in lipid vehicles: is it predictable? Adv. Drug Deliv. Rev. 60(6), 638-656.
Satish, P., Kalyane, N.V., Sarbaniduttagupta, 2014. Design and evaluation of self-micro emulsifying drug delivery systems of acyclovir. Int. J. Pharm. Pharm. Sci. 6(4), 677-681.
Shishu Rajan, S., Kamalpreet, 2009. Development of novel microemulsion-based topical formulations of acyclovir for the treatment of cutaneous herpetic infections. AAPS Pharm. Sci. Technol. 10(2), 559-565.
Susantakumar, P., Gaur, A., Sharma, P., 2011. Comparative pharmacokinetics, safety and tolerability evaluation of acyclovir IR 800 mg tablet in healthy indian adult volunteers under fasting and non-fasting conditions. J. Bioequiv. Availab. 3(6), 128-138.
Sprunk, A., Strachan, S.J., Graf, A., 2012. Rational formulation development and in vitro assessment of SMEDDS for oral delivery of poorly water soluble drugs. Eur. J. Pharm. Sci, 46, 508-515.
Wagstaff, A.J., Faulds, D., Goa, K.L., 1994. Aciclovir A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 47(1), 153-205.
Wilson, C.G., Washington, N., Hardy, J.G., Bond, S.W., 1987. The influence of food on the absorption of acyclovir: a pharmacokinetic and scintigraphic assessment. Int. J. Pharm, 38, 221-225.
Yee, S., 1997. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm. Res, 14, 763-766.
Zhu, C., Jiang, L., Chen, T.M., Hwang, K.K., 2002. A comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur. J. Med. Chem, 37, 399-407.
|
Language: | English.
|
Document Type: | Articles.
|
Journal Subset: | Pharmacology.
|
ISSN: | 0378-5173
|
NLM Journal Code: | da4, 7804127
|
DOI Number: | https://dx.doi.org/10.1016/j.ijp...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|